Loading...
•
Dec 31, 2020
MannKind Q4 2020 Earnings Report
MannKind reported strong Q4 2020 results with increased Afrezza net revenue and collaborations revenue.
Key Takeaways
MannKind Corporation reported financial results for the fourth quarter and full year ended December 31, 2020. The company's Q4 total revenues were $18.4 million, including Afrezza net revenue of $10.1 million and collaborations and services revenue of $8.4 million. They also acquired QrumPharma Inc. for $12.8 million and entered into an agreement to co-promote Thyquidity beginning in Q1 2021.
Afrezza net revenue was $10.1 million, a 30% increase compared to Q4 2019.
Total revenues reached $18.4 million, driven by Afrezza sales and collaborations.
The company acquired QrumPharma Inc. to expand its pipeline of therapies.
A collaboration agreement was established with Vertice for the co-promotion of Thyquidity.
Revenue by Segment
Forward Guidance
MannKind has entered into a non-binding letter of intent for a sale-leaseback of its Danbury manufacturing facility, expected to close in Q1 2021, with proceeds used for general corporate purposes and potential debt reduction.
Positive Outlook
- Sale-leaseback of Danbury facility expected to generate $95 million - $105 million.
- Lease term of 20 years with four 5-year renewal options.
- Annual rent of approximately $10 million - $11 million at the beginning of the lease.
- Proceeds to be used for general corporate purposes.
- Potential paydown of senior secured debt with proceeds.
Challenges Ahead
- Transaction is subject to negotiation of satisfactory definitive agreements.
- Transaction is subject to satisfactory results of buyer’s inspections and investigations.
- There is no assurance that the proposed transaction will be completed in the timeframe.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...